

Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry

Received: 8 July 2025

Accepted: 13 April 2026

Published online: 9 June 2026

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Anxiety is heritable and exists on a continuum, with symptoms ranging from adaptive threat response to clinical disorder. Here we performed a genome-wide association meta-analysis of generalized anxiety symptom severity in 693,869 individuals of European ancestry from 14 cohorts. We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety. SNP-based heritability was 5.9% (posterior s.d. = 0.15%). Polygenic scores were significantly associated with anxiety symptom severity and disorder in European, African and South Asian ancestry samples ($R^2 = 1.2\text{--}2.9\%$). Significant genetic correlations (r_g) were estimated with mental and physical health traits, including case-control anxiety, neuroticism and depression ($r_g = 0.71\text{--}0.85$), irritable bowel syndrome ($r_g = 0.57$), coronary artery disease, endometriosis and migraine ($r_g = 0.20\text{--}0.27$). Gene-based and pathway analyses implicated synaptic and axonal processes, with enriched expression in the brain. These findings highlight the discovery power gained from analysing a quantitative trait rather than a case-control phenotype in anxiety genetics.

Anxiety disorders are the most prevalent mental health conditions worldwide¹ and rates are rising^{2–4}. Anxiety is associated with reduced quality of life⁵, elevated mortality^{6,7} and is frequently comorbid with other mental^{8–12} and physical¹³ health conditions, ranging from irritable bowel syndrome to cancer. When co-occurring with other conditions, anxiety symptoms can exert an independent and sometimes greater impact on quality of life and functioning than the primary diagnosis⁸, as has been reported in autism¹⁴ and bipolar disorder¹⁵.

Twin and family studies estimate the heritability of anxiety disorders at 20–60% (ref. 13), with measures capturing stable anxiety typically showing higher heritability¹⁶. Early case-control genome-wide association studies (GWAS)^{17–19}, which aggregated across anxiety subtypes, identified a handful of risk loci. More recent large-scale efforts using a range of analytical approaches have reported between 14 and 51 associated loci^{20–22}. A recent GWAS²³ of anxiety disorders from the Anxiety Disorders Working Group of the Psychiatric Genomics Consortium

(PGC-ANX) identified 58 independent loci from over 120,000 cases. Across these studies, single nucleotide polymorphism (SNP)-based heritability estimates ranged from 5% to 10% (refs. 20,22,23).

Fear and worry serve an evolutionary function by promoting vigilance and caution in response to potential threats²⁴. Variation in threat sensitivity across individuals may be adaptive at the group level and, consistent with this, anxiety symptoms exist in the population along a continuum of frequency and severity. Clinical anxiety represents a practical threshold at the upper extreme of this distribution based on levels of distress and functional impairment. GWAS of anxiety using quantitative symptom scores capture genetic variation across the full phenotypic range, not only at clinical thresholds. This approach can offer greater statistical power²⁵ and a more comprehensive representation of genetic associations with anxiety traits. The degree of genetic overlap between quantitative anxiety symptom severity and disorder status has received little study. A GWAS of a 2-item anxiety scale in the

✉ e-mail: thalia.eley@kcl.ac.uk




Fig. 1 | Manhattan plot of the genome-wide association meta-analysis of generalized anxiety symptom severity. Variants are represented as points plotted against their respective genomic location and association significance value (two-tailed test). The red line indicates the genome-wide significant threshold ($P < 5 \times 10^{-8}$). Sample size, $N = 693,869$.

European ancestry subsample of the Million Veteran Program (MVP) identified 5 significant loci²⁶ and moderate-to-strong genetic correlations with lifetime anxiety disorder ($r_g = 0.59$ – 0.87)^{13,26}. However, the brevity of the measure may have limited the potential to comprehensively capture phenotypic variance. Additional support for shared genetic signal across the anxiety continuum, including above and below diagnostically relevant thresholds, comes from a UK Biobank study¹⁹ reporting high genetic correlations between mild, moderate and severe anxiety symptom groupings ($r_g = 0.76$ – 0.98). Among individuals with lifetime anxiety or depression, anxiety symptom severity has also shown a significant genetic correlation with functional impairment ratings ($r_g = 0.79$)²⁷, which have clinical relevance.

These findings provide preliminary evidence that a well-powered GWAS of quantitative anxiety would identify variants relevant to both symptom severity and clinically defined anxiety. Aside from the MVP analysis of a two-item scale, previous quantitative anxiety GWAS^{28,29} have incorporated other psychiatric or personality traits to maximize statistical power, resulting in findings relating to a broader construct than anxiety symptoms specifically. To address this, we performed a genome-wide association meta-analysis of generalized anxiety disorder (GAD) symptom severity in 693,869 individuals of inferred European ancestry across 14 cohorts from PGC-ANX, building on our previous study²³ of individuals with anxiety disorder. Most cohorts used the GAD 7-item scale (GAD-7) or conceptually similar self-report measures of recent GAD symptoms. In addition to identifying associated loci, we performed variant- and gene-level investigations, estimated genetic correlations with relevant traits and evaluated polygenic score prediction in independent samples of European, African and South Asian ancestry.

Results

Genome-wide association meta-analysis

We performed a genome-wide association meta-analysis of GAD symptom severity in 693,869 individuals of European ancestry across 14 cohorts from 8 countries (see Supplementary Tables 1–3 for cohort, phenotype and GWAS details). The analysis identified 80 independent genome-wide significant variants ($P < 5 \times 10^{-8}$) across 74 loci (Fig. 1, Supplementary Fig. 1 and Supplementary Table 4). Effect sizes (β) represent the associated change in standard deviation units of generalized anxiety symptom score per additional copy of the effect allele. The top signal came from an intergenic locus near the long non-coding RNA

RP4-598G3.1 on chromosome 1 (lead SNP **rs7546305**; $P = 3.8 \times 10^{-15}$; $\beta = -0.014$; 95% confidence interval (CI), -0.017 to -0.010), followed by a locus within an intron of *PCLO* on chromosome 7 (lead SNP **rs1476548**; $P = 4.9 \times 10^{-15}$; $\beta = -0.014$; 95% CI, -0.017 to -0.010). These loci have both previously been associated with internalizing traits, including anxiety (Supplementary Table 5).

Of the 74 loci, 16 had no previous associations with internalizing trait GWAS, including neuroticism, anxiety or depression, at any variant in linkage disequilibrium (LD; defined as $r^2 > 0.1$) with the lead SNP (Methods and Supplementary Table 5a). Thirty-nine loci were novel for anxiety specifically, measured either as a diagnosis or symptom severity phenotype. Of the 58 loci previously identified in the PGC-ANX anxiety disorder study²³, all showed the same direction of association in the present analysis, with 19 (33%) reaching genome-wide significance and a further 33 (57%) showing nominal significance ($P < 0.05$) (Supplementary Table 5b). Nine of the 14 cohorts included here also contributed to the PGC-ANX anxiety disorders study, although cohort sample composition differed somewhat due to the availability of symptom score versus diagnostic information. Power calculations³⁰ confirmed increased power in the present analysis relative to the anxiety disorder study (Supplementary Table 6).

Among the 6,012 genome-wide significant SNPs, between-study heterogeneity accounted for a moderate proportion of variance in effect size estimates (measured with I^2), with a median I^2 across cohorts of 29.7%. In contrast, the median I^2 for the 80 LD-independent genome-wide significant SNPs was 0%, indicating highly consistent effect size estimates across cohorts. Heterogeneity statistics for the lead SNPs are presented in Supplementary Table 4. Genetic correlations between sufficiently powered cohorts, estimated using LD score regression (LDSC), ranged from 0.64 to 0.97 (significant at a Bonferroni-corrected threshold $P < 4.6 \times 10^{-4}$; Supplementary Table 7). As a sensitivity analysis, we categorized cohorts by generalized anxiety symptom severity measure (for example, GAD-7; six subgroups) and by ascertainment method (community and clinical subgroups) (Supplementary Table 2). Subgroup meta-analyses were performed as per the main analysis, and genetic correlations between subgroups were estimated with LDSC. While most subgroup comparisons were underpowered, including by ascertainment method, the genetic correlation between the 2 most frequently used measures was high (GAD-7 and GAD-2, $r_g = 0.86$; 95% CI, 0.79 – 0.92 ; $P = 9.6 \times 10^{-166}$, significant at a Bonferroni-corrected threshold $P < 5 \times 10^{-3}$; Supplementary Table 8).




Fig. 2 | Genetic correlations between generalized anxiety symptom severity meta-analysis and a range of traits from existing GWASs. Genetic correlations estimated using LDSC ($N = 693,869$). All correlations shown are significant at a Bonferroni-corrected threshold for 105 tests (2-tailed $P < 4.76 \times 10^{-4}$). Points represent genetic correlation estimates and bars represent 95% CIs. Exact P

values and full results for all tested traits are provided in Supplementary Table 9. Forced expiratory volume is a measure of lung function. ADHD, attention-deficit/hyperactivity disorder; BMI, adult body mass index; EA, educational attainment; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder; SES, socio-economic status.

SNP-based heritability and genetic correlations with external traits

The SNP-based heritability estimate from SBayesRC was 5.90% (posterior s.d. = 0.146%). SBayesRC was selected due to the known underestimation of heritability from LDSC³¹. LDSC³² indicated that genomic inflation was largely not attributable to confounding (intercept = 1.03; 95% CI, 1.01–1.05). To characterize the broader genetic architecture of GAD symptoms, we used LDSC³³ to estimate genetic correlations with 105 traits spanning mental and physical health, personality, cognitive and socio-economic domains (Supplementary Table 9). Following Bonferroni correction ($P < 4.8 \times 10^{-4}$), 64 associations remained significant (Fig. 2, omitting 4 traits represented by multiple studies).

The strongest correlations were observed with quantitative internalizing traits, including neuroticism, depressive symptoms and a genetic anxiety factor ($r_g = 0.83$ – 0.86), and with case-control phenotypes for anxiety and depression ($r_g = 0.71$ – 0.80). Moderate-to-strong estimates were also found for post-traumatic stress disorder

($r_g = 0.64$), insomnia ($r_g = 0.49$), irritable bowel syndrome ($r_g = 0.57$) and chronic pain ($r_g = 0.56$). Negative correlations were observed with socio-economic status indicators including household income ($r_g = -0.43$). Smaller but significant correlations were identified with coronary artery disease, endometriosis, hypothyroidism and migraine ($r_g = 0.20$ – 0.27). Most other associations with physical traits and illnesses were comparatively weaker and included positive correlations with resting heart rate, rheumatoid arthritis and atopic dermatitis, and a negative correlation with lung function (absolute $r_g = 0.06$ – 0.13).

Conditional analyses

To assess whether genome-wide significant loci for generalized anxiety symptoms represented associations unique to this phenotype, we performed multi-trait conditional and joint analysis (mtCOJO)³⁴, conditioning on highly genetically correlated traits. mtCOJO uses Generalized Summary-data-based Mendelian Randomization (GSMR) to estimate the effect of a conditioning trait on an outcome (b_{xy}). Conditioning

on neuroticism (67 instruments, $\text{GSMR } b_{xy} = 0.47 \pm 0.02$) resulted in 9 remaining genome-wide significant SNPs across 2 loci ($P < 5 \times 10^{-8}$; Supplementary Table 10). Conditioning on case-control anxiety (11 instruments, $b_{xy} = 0.22 \pm 0.02$) yielded 66 significant SNPs across 6 loci, and conditioning on case-control depression (98 instruments, $b_{xy} = 0.31 \pm 0.01$) produced 76 SNPs across 6 loci. Approximately half of SNP effect sizes were attenuated and standard errors had a median inflation of 7–9%, suggesting the loss of significance was not solely attributable to reduced power. Sign changes were observed in 17–20% of variants for each trait, consistent with instability, as expected under high genetic correlations. The LDSC SNP-based heritability (h^2) estimates of the conditioned summary statistics were significant (neuroticism $h^2 = 0.014$; 95% CI, 0.012–0.016; $P = 1.02 \times 10^{-42}$; case-control anxiety $h^2 = 0.018$; 95% CI, 0.016–0.020; $P = 1.54 \times 10^{-59}$; case-control depression $h^2 = 0.017$; 95% CI, 0.015–0.019; $P = 7.34 \times 10^{-51}$), but block jack-knifing confirmed that each was significantly lower than the original estimate (Z -statistic = 33.24, $P = 3.3 \times 10^{-242}$; $Z = 28.61$, $P = 5.0 \times 10^{-180}$; $Z = 30.48$, $P = 4.24 \times 10^{-204}$, respectively).

Polygenic risk scores

To evaluate the within- and cross-ancestry generalizability of our GWAS findings, we generated a polygenic risk score (PRS) for GAD symptom severity using SBayesRC³⁵ and tested its association with both quantitative and case-control anxiety outcomes in independent samples across ancestry groups (Supplementary Table 11). A Bonferroni-corrected significance threshold of $P < 1.7 \times 10^{-2}$ was applied, accounting for 3 ancestry groups tested per outcome. The PRS significantly explained 2.9% of the variance (R^2) in generalized anxiety symptom scores in an independent European ancestry sample ($\beta = 0.55$; 95% CI, 0.44–0.65; $P = 8.9 \times 10^{-24}$), 1.4% in an African ancestry sample ($\beta = 0.48$; 95% CI, 0.28–0.67; $P = 2.9 \times 10^{-6}$) and 1.2% in a South Asian ancestry sample ($\beta = 0.45$; 95% CI, 0.27–0.64; $P = 2.0 \times 10^{-6}$). For case-control anxiety, assuming 20% prevalence, the PRS explained 1.8% ($\beta = 0.25$; 95% CI, 0.14–0.36; $P = 1.2 \times 10^{-5}$) of the variance on the liability scale in a European ancestry sample, 1.7% ($\beta = 0.27$; 95% CI, 0.10–0.44; $P = 2.0 \times 10^{-3}$) in an African ancestry sample and 1.4% ($\beta = 0.25$; 95% CI, 0.10–0.41; $P = 1.3 \times 10^{-3}$) in a South Asian ancestry sample. These R^2 values represent the variance explained by the PRS beyond that accounted for by covariates.

Positional and functional annotation

Functionally informed fine-mapping using PolyFun³⁶ and SuSiE³⁷ identified 4 putative causal variants with posterior inclusion probabilities (PIP) ≥ 0.95 . Two of these were index variants for genome-wide significant loci: **rs2392289** at locus 31 (PIP = 0.983) and **rs72676302** at locus 58 (PIP = 0.978). The remaining two variants were in loci that did not reach genome-wide significance. One variant, **rs72676302**, had a high Combined Annotation Dependent Depletion (CADD) score of 19.78, suggesting a deleterious effect (above the suggested threshold of 12.37 (ref. 38)), although there was little biological evidence that it is within a regulatory element (regulomeDB score = 5). In addition, we identified 24 small credible causal sets (<10 variants each) that cumulatively met the PIP threshold (Supplementary Table 12).

SNP-level gene annotation was performed using FUMA³⁹ based on positional, expression quantitative trait loci (eQTL), and chromatin interaction (Hi-C) mapping (Supplementary Table 13). We identified genes annotated by more than one method, with this convergence providing greater support for their involvement. This approach again highlighted *PCLO* and *CRHR1*, a key regulator of the stress response, along with *TMEM106B*, which has been repeatedly associated with anxiety^{18,19,23} and with depression⁴⁰. *SORCS3* was implicated by both positional and chromatin interaction mapping and has also been reported in a previous anxiety GWAS²³. In addition, multiple genes were identified that have previously been implicated in depression (for example, *ERBB4*, *GRM7*, *VRK2*, *DCC*, *LRFN5*, *PCLO* and *NEGR1*) and schizophrenia (for example, *ERBB4*, *VRK2* and *NEGR1*). *MAD1L1* (refs. 17–19,26) was

supported only by positional mapping in our analysis but has been linked to anxiety phenotypes in previous GWAS, lending further support to its potential relevance. Although detailed functional information was limited for many mapped genes, several are posited to play roles in key neurotransmitter systems, including glutamatergic (*GRM7* and *HOMER1*), GABAergic (*ERBB4*) and dopaminergic (*DRD1*) signalling. In contrast, gene annotations for loci novel for internalizing traits did not map clearly to defined neurobiological pathways relevant to anxiety. For example, **rs58179213** is proximal to multiple genes implicated in diverse biological processes, including lung function (*SFTPC*), intestinal barrier function and immunoprotective inflammation (*FHBP2B*), and hair growth (*HR*). While such processes could influence anxiety via indirect pathways (for example, gut–brain interactions or somatic symptoms), independent replication will be required to provide the greater power necessary to determine their robustness and relevance.

Gene-based associations and enrichment

Gene-based association analysis was conducted using MAGMA⁴¹, which aggregates trait-SNP associations across all SNPs within a gene while accounting for LD. In total, 197 genes across 80 independent loci surpassed the Bonferroni-corrected significance threshold ($P < 2.5 \times 10^{-6}$; Supplementary Table 14). The top associated gene was *PCLO* ($P = 2.5 \times 10^{-21}$), mirroring the SNP-based results.

To assess biological pathways significantly enriched for associations with GAD symptom severity, we performed pathway analysis in MAGMA with predefined gene sets (MsigDB⁴²; curated and Gene Ontology terms; Supplementary Table 15.a). Six gene sets passed Bonferroni correction ($P < 2.9 \times 10^{-6}$): postsynaptic membrane (271 genes, $P = 2.6 \times 10^{-8}$), synaptic membrane (383 genes, $P = 7.1 \times 10^{-8}$), axon (627 genes, $P = 5.3 \times 10^{-7}$), neurogenesis (1,627 genes, $P = 8.6 \times 10^{-7}$), postsynapse (648 genes, $P = 9.2 \times 10^{-7}$) and generation of neurons (1,412 genes, $P = 1.0 \times 10^{-6}$). These results were unaffected by the exclusion of the major histocompatibility complex region, although the number of genes per set slightly decreased (Supplementary Table 15b).

Gene–tissue expression analysis was conducted using catalogues of gene expression levels across different human tissues (Supplementary Fig. 2–5), with a Bonferroni correction applied for the number of tests within each tissue set. Among brain samples from 11 developmental stages (BrainSpan), only the 2 prenatal samples were significant ($P = 6.3 \times 10^{-4}$ and 2.5×10^{-3}). In adult tissues (GTEx v.8 (ref. 43)), significant enrichment was observed in brain ($P = 3.0 \times 10^{-9}$) and pituitary ($P = 4.9 \times 10^{-5}$) tissues. Analysis of more specific tissue types revealed enrichment in 11 brain regions, most strongly in the frontal cortex, cortex, cerebellum, anterior cingulate cortex and nucleus accumbens (all $P < 9.3 \times 10^{-4}$; Supplementary Table 16).

Drug targets

To explore therapeutic relevance, we ran DrugTargetor⁴⁴ to identify drug priorities with potential utility for clinical anxiety, based on their relevance for GAD symptom severity. We did not observe any significant enrichment of anxiety associations for the 1,551 drug targets tested (Supplementary Table 17). However, at the drug class level, we identified significant associations for Anatomical Therapeutic Chemical classifications N06 ‘psychoanaleptics’, including N06A antidepressants, N02A ‘opioids’ and N06B ‘psychostimulants’ (Bonferroni-adjusted $P < 0.05$; Supplementary Table 18). With the exception of psychostimulants, these classes include drugs that have been used clinically to treat anxiety⁴⁵. The enrichment for psychostimulants probably reflects shared dopaminergic and noradrenergic pathways involved in arousal and vigilance and underlying both anxiety and attention, consistent with pleiotropic genetic associations rather than direct therapeutic action.

Discussion

In this genome-wide association meta-analysis of 693,869 individuals from 14 cohorts, we identified 80 genome-wide significant variants

across 74 loci associated with quantitative measures of GAD symptom severity. Approximately half of the identified loci replicated associations reported in previous anxiety GWAS^{19–23,46}, while the remainder were newly identified associations.

The strongest intragenic association was estimated for *rs1476548* within *PCLO*, which was also implicated through positional mapping, eQTL mapping and gene-based association testing. *PCLO* encodes a protein involved in regulating presynaptic structure and neurotransmitter release. This gene has long been of interest in major depressive disorder⁴⁷, with recent evidence also linking it to anxiety disorders^{20,23}. Another gene of interest from our analysis was *SORCS3*, which was supported by multiple lines of evidence in the recent PGC-ANX case–control anxiety GWAS²³. *SORCS3* plays a role in postsynaptic functioning and glutamate receptor regulation, particularly in the hippocampus⁴⁸. It has been linked to memory and learning processes, specifically synaptic depression and fear extinction⁴⁹, and mental health and neurodevelopmental conditions, including major depressive disorder, Tourette syndrome, attention deficit hyperactivity disorder and autism^{50,51}.

Our SNP-based heritability estimate (5.9%) aligned with an existing GWAS of GAD symptom severity (5.6%)²⁶ while remaining lower than liability scale estimates from case–control anxiety meta-analyses²³. In contrast to traditional case–control phenotyping, which aims to maximize clinical specificity through diagnostic thresholds, our approach leveraged the full spectrum of symptom variability, increasing power for discovery⁵² and capturing genetic risk relevant to both subclinical and clinical presentations. The key differences between clinical diagnoses and symptom severity measures relate to the presence of distress and impairment and to symptom duration. While subclinical symptoms can still cause distress and impairment, this is not always true for lower levels of anxiety severity, potentially contributing to some diagnosis-specific genetic variance. Similarly, diagnostic tools often assess lifetime occurrence and require symptoms to be present for a minimum period of time (6 months for GAD), whereas symptom severity scales typically capture recent experiences (for example, the past 2 weeks), introducing greater susceptibility to transient fluctuations and measurement noise. Consistent with this, GWAS^{33–55} of depression symptom severity typically yield lower SNP-based heritability estimates than case–control analyses. We aimed to partially address and control for temporal fluctuations and better approximate a stable underlying trait¹⁶ by incorporating assessments from multiple time points into our analysis, where available. In addition, our meta-analysis combined data from multiple cohorts with differences in phenotype definitions, genotyping arrays, imputation methods, quality control procedures and population structure adjustments, which may have introduced further heterogeneity and reduced the observed SNP-based heritability. By contrast, single-cohort studies with individual-level data are more homogeneous and can implement alternatives to summary-statistics-based methods. Despite our lower heritability estimate, the strong genetic correlation observed between our phenotype and case–control anxiety suggests that GAD symptom severity captures much of the same genetic risk. This finding is consistent with a recent analysis of obsessive–compulsive symptoms⁵⁶. Quantitative, symptom-based approaches may be particularly well suited to genetic studies of anxiety, given the high burden of anxiety symptoms observed across other mental health conditions^{8–11}. In this context, efforts to isolate ‘pure’ anxiety cases may be both methodologically challenging and capture an unusual clinical phenotype that is unrepresentative for most individuals with anxiety.

There was a broad range of significant genetic correlations across both mental and physical health conditions, consistent with the frequent co-occurrence with anxiety symptoms and widespread pleiotropy. A strong genetic correlation was observed with neuroticism, a well-established risk factor for anxiety²³. This probably reflects both genuine shared liability and conceptual or item-level overlap between the measures. Conditional analyses indicated extensive

overlap between loci associated with generalized anxiety symptoms and those implicated in neuroticism, case–control anxiety and depression. Many genome-wide significant loci may therefore index a broader neuroticism-related liability, although the presence of anxiety-specific associations cannot be excluded due to the statistical noise introduced by conditioning on highly genetically correlated traits. Many of the genetic correlations aligned with findings from a genomic structural equation modelling analysis of anxiety symptoms and disorder²², including strong associations with irritable bowel syndrome and chronic pain, and a moderate association with migraine. These results do not necessarily indicate horizontal pleiotropy but could instead arise from the experience of these conditions eliciting uncertainty and worry that contribute to anxiety.

Polygenic scores derived from our genome-wide association meta-analysis demonstrated within- and cross-ancestry generalizability, significantly explaining 1.2–2.9% of the variance in GAD symptom severity in European, African and South Asian ancestry samples. Across these samples, the PRS also accounted for 1.4–1.8% of the variance in case–control anxiety on the liability scale. While broadly consistent with the 0.5–2.3% range reported in the PGC-ANX case–control analysis²³, direct comparisons are limited by methodological differences in PRS construction and target sample composition. A key limitation of the present meta-analysis is its restriction to cohorts of European ancestry, due to lack of data for other ancestries at sufficient scale for GWAS analysis. Our PRS findings support a degree of shared genetic architecture with African and South Asian populations. Ancestry-specific modelling across diverse populations remains necessary to identify population-specific risk loci, such as that identified in a previous analysis²⁶ of African American participants, and ensure equitable benefits from genetic discoveries. Overall, these findings provide additional evidence that quantitative phenotyping can effectively capture genetic signal relevant to clinical anxiety.

The GAD symptom severity measures and ascertainment methods varied across contributing cohorts, although most assessed symptoms using the GAD-7. While widely adopted across clinical and research contexts, the GAD-7 does not comprehensively assess all GAD symptoms from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)⁵⁷—omitting sleep, fatigue and concentration problems—and is not designed to capture symptoms of fear-based anxiety (that is, phobias and social anxiety disorder) or panic disorder. This limits the generalizability of our findings across anxiety disorders, particularly in light of evidence for partially distinct phenotypic and genetic contributions to GAD compared with fear-based disorders^{58,59}. Expanding future studies to incorporate a broader range of anxiety symptom measures will enable more robust, transdiagnostic translation of these findings. Furthermore, future work could examine the genetic architecture of individual symptom domains, such as cognitive versus physiological symptoms, to better understand the biological specificity of these. Our subgroup analyses based on measure and ascertainment method were largely underpowered to reliably estimate SNP-based heritability or correlations. Although sufficiently powered comparisons indicated high genetic overlap, we cannot be certain that all cohorts captured the same underlying genetic architecture. While population-based cohorts allow assessment of the full range of symptoms, symptom severity measures typically better distinguish variation at the upper end of the distribution. This results in highly skewed symptom severity scores, as most participants report few or no symptoms, whereas individuals in clinical cohorts typically report more symptoms. Combining population-based cohorts with studies selecting on diagnosis introduces some heterogeneity and may limit generalizability to broader populations, but it can help yield a more normally distributed phenotype for GWAS analysis. This combination may have improved statistical power for detecting associations in our study.

Our quantitative GWAS of GAD symptom severity identified more genome-wide significant loci than a slightly larger and mostly

overlapping case–control anxiety study ($N = 852,222$; 122,341 cases)²³, with many loci replicated across the 2 methods. This aligns with expectations under the liability-threshold model when considering common conditions such as anxiety, whereby quantitative traits generally offer greater statistical power than case–control designs of equal sample size⁵². Beyond identifying anxiety-associated loci, our results implicate key neurobiological pathways, including synaptic function and neurotransmission, and notable genes such as *PCLO* and *SORCS3*. These findings demonstrate that a quantitative anxiety symptom-based phenotype can reveal biologically meaningful signals and complements insights from case–control designs. Clinically ascertained samples remain essential for identifying disorder-specific biology and mapping genetic risk to diagnostic presentations; however, obtaining clinical cases at sufficient scale for binary genome-wide analyses is challenging. Although electronic health records offer an efficient option, these are limited to individuals seeking and receiving medical attention. Quantitative, symptom-based approaches within biobanks and population studies therefore offer a promising scalable alternative for advancing the field of anxiety genetics. Moving forwards, the combination of these with deeply phenotyped clinical cohorts will be crucial for translating genetic insights into diagnostic and therapeutic advances. Together, these approaches can elucidate the biological continuum of anxiety, from healthy stress responses to debilitating disorder. Given the high and rising rates of anxiety, especially in young adults, it is more important than ever to improve our ability to identify and understand sources of risk. Despite its public health impact, progress in anxiety genetics lags behind other major mental health conditions. We hope our findings encourage genome-wide investigations leveraging existing but potentially underutilised anxiety severity data in genotyped cohorts, accelerating our progress in understanding the genetic architecture of anxiety.

Methods

Participants and measures

We meta-analysed data from 14 international cohorts ($N = 693,869$): 13 PGC-ANX studies with generalized anxiety symptom data and summary statistics from a pre-existing GWAS²⁶. Details of each study and sample descriptives are provided in Supplementary Table 1. We performed a meta-analysis with access to individual participant data⁶⁰, such that each PGC-ANX cohort performed genome-wide association analyses specifically for this study and shared summary statistics with the core analytical team. The majority of the sample (70%) had completed the GAD-7 or closely related brief self-report measures assessing recent anxiety symptoms. The remaining 30% used other brief self-report anxiety scales (Supplementary Table 1), each available in at least 3,000 individuals. We analysed total sum scores, with higher scores indicating greater severity of symptoms. If participants were missing data on <25% of measure items, the missing scores were imputed with the participant's mean score of the other items. Participants with $\geq 25\%$ missing data were excluded from analysis. Several cohorts had assessed anxiety symptoms on two or more occasions. Longitudinal twin studies have shown that symptom stability is primarily driven by genetic factors^{16,61,62} and that stability extracted from repeated assessments yields higher heritability estimates than single time points¹⁶. For cohorts with anxiety assessments from 3 or more time points (12% of the sample), a latent factor was created in R with the package *lavaan*⁶³, the predict function and a maximum likelihood estimator. For cohorts with 2 time points (44%), a mean score was calculated. All scores, whether single time point, mean or factor score, were standardized to have a mean of zero and a standard deviation of one. Given the high comorbidity of anxiety and other mental health conditions, no additional exclusions were applied beyond those defined by each study. For two cohorts—Genetic Links to Anxiety and Depression Study (GLAD+) and the UK Biobank—individual-level data were merged before the GWAS. Participants from clinical cohorts had been recruited based on a lifetime history of depression or anxiety, as assessed by self-reported diagnostic questionnaires.

Meta-analysis

Supplementary Table 3 provides details of the studies that contributed to this meta-analysis, which were: Australian Genetics of Depression Study (AGDS)⁶⁴, Avon Longitudinal Study of Parents and Children (ALSPAC)^{65,66}, CoLaus|PsyCoLaus⁶⁷, Estonian Biobank⁶⁸, Generation Scotland⁶⁹, NIHR Bioresource GLAD+⁷⁰, Lifelines⁷¹, MEGA TRR58⁷², MVP²⁶, Norwegian Mother, Father and Child Cohort Study⁷³, Providing Tools for Effective Care and Treatment of Anxiety Disorders (PROTECT-AD)⁷⁴, Twins Early Development Study (TEDS)⁷⁵, Tracking Adolescents' Individual Lives' Survey (TRAILS)⁷⁶ and UK Biobank⁷⁷. Each cohort performed genotyping using microarray platforms and imputed genotypes using ancestry-matched panels, primarily the Haplotype Reference Consortium⁷⁸. Standard quality control procedures were applied, including filters on sample and variant call rates, sex concordance and excessive heterozygosity (full details in Supplementary Table 3). The one set of pre-existing summary statistics was from an analysis in the MVP, obtained through the database of Genotypes and Phenotypes (dbGaP; phs001672). Most groups adopted a mixed linear model approach and retained related individuals in their GWAS. Where applicable, covariates such as ancestry principal components and genotyping batch were included. We did not include age or sex as covariates, as they are not confounders of genetic effects and may represent effect moderators of interest warranting dedicated follow-up investigation, rather than variables to be adjusted for. All resulting summary statistics were on the GRCh37 genome assembly (build 37, hg19). Before meta-analysis, variant-level quality control was performed across the summary statistics, excluding those with minor allele frequency <1% or imputation accuracy score <0.6. Variants present in fewer than half of the contributing cohorts were excluded, resulting in a total of 7,499,431 autosomal SNPs. X-chromosome data were analysed from 7 cohorts (166,852 variants), with male genotypes coded as diploid (0/2) and sex included as a covariate. The meta-analysis was conducted in METAL (v.2020-05-05)⁷⁹ using an inverse-variance-weighted, standard-error-based approach. The β values from the meta-analysis represent the associated change in standard deviation units of generalized anxiety symptom score per additional copy of the effect allele. All statistical tests conducted in this study were two tailed.

Heterogeneity across cohorts was assessed by inspecting the P values from Cochran's Q test as implemented in METAL. In addition, we calculated the median I^2 values (HetI_{Sq} in METAL) for SNPs reaching genome-wide significance ($P < 5 \times 10^{-8}$) and for independent lead SNPs. We also estimated genetic correlations between contributing cohorts using LDSC³³. The inclusion of clinical alongside community-based cohorts offered greater representation across the full range of anxiety symptom severity, increasing statistical power as evidenced in a recent depression GWAS⁸⁰. However, due to the risk of bias or confounding from differences in study design and phenotyping, we performed subgroup meta-analyses stratified by anxiety measure and excluding clinical cohorts (Supplementary Table 2). Meta-analyses of the measure and ascertainment subgroups were performed in METAL, and genetic correlations between the groups estimated using LDSC³³. For both cohort and subgroup genetic correlations, most pairwise comparisons were not sufficiently powered (that is, heritability z -scores <4 for 1 or both sets of summary statistics⁸¹) to draw conclusions.

To identify LD-independent significant SNPs and loci, clumping was performed in FUMA (v.1.6.5)³⁹. The r^2 threshold for independent significant SNPs was 0.1, and was 0.05 for lead SNPs, within a 500-kb window. Genome-wide significance was defined using the conventional threshold ($P < 5 \times 10^{-8}$).

To identify novel loci in our results, we cross-referenced significant loci with published trait associations from the GWAS Catalog⁸² using LDTrait⁸³ (date accessed 2 September 2025), applying an r^2 threshold of >0.1 and a 500-kb window. Novelty was strictly defined as having no previous associations with internalizing traits including anxiety, depression, neuroticism and worry. To supplement this, we compared

our results with recent anxiety and depression studies^{23,80} not yet available in the GWAS Catalog. Overlapping significant loci were identified with BEDtools (v.2.31.0)⁸⁴ and LD assessed using a threshold of $r^2 > 0.1$. The investigation of novel loci also revealed the extent to which our results replicated previous findings. We also determined novel loci specifically for anxiety, whether assessed as symptom severity or a case-control phenotype. Many of the 14 cohorts in our meta-analysis overlap with previous case-control anxiety meta-analyses, with the exception of GLAD+, Lifelines, PROTECT-AD, TEDS and MEGA (approximate $N = 110,000$). In some instances, the cohort sample composition differs due to the availability of quantitative versus diagnostic information.

SNP-based heritability and genetic correlations with external traits

We estimated SNP-based heritability via SBayesRC (v.0.2)³⁵. This provided an estimate of the proportion of variance in quantitative anxiety attributable to variation in the common SNPs present in this meta-analysis. We inspected the LDSC³² genomic inflation factor (λ_{GC}) and intercept to evaluate the contribution of potential confounding relative to polygenicity. Genetic correlations were also computed using LDSC with 105 GWAS summary statistics covering a broad range of phenotypes and applying a Bonferroni-corrected P value threshold of 4.76×10^{-4} .

High genetic correlations, such as those often observed between anxiety, depression and neuroticism, do not necessarily indicate identical biology; even when most loci are shared, traits may involve different biological pathways, tissue enrichments or show individual patterns of relationships with other traits. Identifying unique genetic influences on anxiety is important to better understand its specific aetiology and inform potential treatment pathways. However, conditional analyses, especially in the presence of strong genetic correlations, are statistically challenging and require substantial power, and therefore should be interpreted cautiously. We used the mtCOJO³⁴ tool from GCTA (v.1.94.1), which performs conditional analyses between summary statistics to provide marginal effect estimates for the trait of interest. We conditioned our anxiety meta-analysis on depression diagnosis⁸⁰ (98 index SNPs), neuroticism⁸⁵ (67 index SNPs) and anxiety diagnosis²³ (11 index SNPs). Depression symptoms⁸⁶ was underpowered (two index SNPs) for the analysis. We also estimated the SNP-based heritability of each set of conditioned summary statistics with LDSC and used block jack-knifing to compare these to the unconditioned heritability estimate.

PRSs

To evaluate the within- and cross-ancestry validity of our GWAS, we calculated GAD symptom severity PRSs in independent samples from the UK Biobank⁷⁷ and Prospective Imaging Study of Ageing (PISA)⁸⁷. We then performed regressions between our PRS and quantitative anxiety, using GAD-7 scores, and case-control anxiety, as defined by a self-reported diagnostic questionnaire or self-report of a diagnosis from a health professional. Specifically, we used SBayesRC³⁵ to calculate PRSs in European, African and South Asian ancestry samples, excluding related individuals. SBayesRC is a Bayesian regression method that uses GWAS summary statistics to estimate SNP effect sizes while accounting for LD and polygenic architecture. It extends the SBayesR framework by incorporating functional annotations or prior biological information, improving the detection of probable causal variants and enhancing predictive accuracy for complex traits. We conducted linear regressions to assess the variance explained in GAD symptom severity by the PRS in each sample (European $N = 3,452$; African $N = 1,581$; South Asian $N = 1,813$). For case-control status, we performed logistic regressions to estimate associations in the target samples (European total $n = 3,107$, case $n = 407$; African total $n = 1,303$, case $n = 218$; South Asian total $n = 1,549$, case $n = 265$). We calculated Nagelkerke's R^2 for our PRS on the liability scale using the observed linear regression R^2 and

corresponding formula⁸⁸, assuming a population prevalence of 20%. All regressions included the first ten ancestry-specific principal components and genotyping batch as covariates. The variance explained by the PRS was calculated as the difference in R^2 between a full model, including the PRS and covariates, and a null model with only covariates.

Positional and functional annotation

We used PolyFun (v.1.0.0)³⁶ to estimate per-SNP heritabilities, leveraging a regularized extension of stratified-LDSC applied to the v.2.2UKB baseline-LF model annotations, which captures heritability enrichment related to allele frequency, LD and variant function. These prior causal estimates were then used for fine-mapping in SuSiE (v.0.11.92)³⁷, limiting to a maximum of one causal SNP per locus. We extracted annotations at a PIP threshold of ≥ 0.95 and created credible causal sets containing the minimum set of ranked variants that cumulatively met this threshold. Unlike standard definitions of credible causal sets in SuSiE, we did not require a minimum pairwise r^2 between variants in a set, as the PolyFun + SuSiE pipeline does not incorporate LD estimates.

We performed SNP-level gene annotation using FUMA (v.1.6.5)³⁹, integrating three complementary methods: positional mapping (based on physical proximity to genes), eQTL mapping (linking variants to gene expression) and chromatin interaction mapping (using Hi-C data to identify regulatory interactions). eQTL mapping used significant SNP-gene pairs and eQTLs from the brain tissue datasets GTEx v.8 Brain⁴³ (13 regions) and BRAINEAC⁸⁹ (10 regions), and averaged expressions across these, applying a false discovery rate (FDR) threshold of $P < 0.05$. Chromatin interaction mapping used Hi-C brain tissue data (dorsolateral prefrontal cortex, hippocampus and left and right ventricles)⁹⁰ and adult and fetal cortex⁹¹, with an FDR threshold of $P < 1 \times 10^{-6}$. These methods differ in their underlying biological rationale and may implicate different genes. Genes identified by two or more mapping approaches were therefore highlighted, as convergence across the methods increased our confidence in the potential functional relevance of a gene.

Gene-based associations and enrichment

Gene-based association, gene-set and gene-tissue expression enrichment analyses were performed in MAGMA (v.1.08)⁴¹ via FUMA (v.1.6.5)³⁹. These analyses aimed to identify genes associated with GAD symptom severity, biological pathways enriched for associated genes and relevant tissues where genes are preferentially expressed, offering insight into the potential biological mechanisms underlying our findings. For gene-based associations, we tested 19,954 genes, applying a Bonferroni-corrected significance threshold of $P < 2.5 \times 10^{-6}$. SNPs were mapped to genes using a 35-kb upstream and 10-kb downstream window. Gene-set analyses were performed using 6,494 curated gene sets (c2.all) and 10,529 Gene Ontology terms (c5.bp, c5.cc and c5.mf) from the Molecular Signatures Database (MSigDB; v.2023.1.Hs)⁴². Significance was determined by a Bonferroni-corrected threshold of $P < 2.9 \times 10^{-6}$. For tissue enrichment, we tested relationships between trait-associated genes and gene expression in human tissues, using data from BrainSpan (brain samples from 11 general developmental stages and 29 specified ages) and GTEx v.8 (covering 30 general and 54 specific tissue types).

Drug targets

We examined whether genes associated with GAD symptom severity were associated with individual drugs and drug classes using the Drug-Targetor (v.1.3)⁴⁴ method. DrugTargetor integrates MAGMA gene-level association results with curated drug-gene interaction databases (ChEMBL^{92,93} and DGIdb⁹⁴). We used MAGMA (v.1.10) to prioritize associated genes within windows 35 kb upstream and 10 kb downstream. We restricted our analysis to hypothesized drug action within the nervous system, a maximum of 1,551 unique drugs and 163 drug classes. To assess the enrichment of drug classes, we calculated the area under the

enrichment curve (AUC), where 50% indicates random enrichment and 100% optimal enrichment, and AUC significance was assessed using one-sided Wilcoxon–Mann–Whitney tests.

Ethics

This study analysed pre-existing data from cohort studies. Each contributing study obtained ethical approval from the relevant institutional ethics committee, and participants provided informed consent permitting genetic and health-related research. Details of all ethical approvals are provided in Supplementary Table 1, and data application numbers where applicable.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Summary statistics are available on the PGC download page (<https://pgc.unc.edu/for-researchers/download-result>). Individual study data can be accessed following review and approval by the individual study cohorts; see <https://pgc.unc.edu/for-researchers/individual-level-data-access/> for more information. Summary statistics for the genetic correlations are available following the procedure detailed within the relevant publications (searchable using the PMID in Supplementary Table 9) or via GWAS Catalog (<https://www.ebi.ac.uk/gwas/home>).

Code availability

Analytical code is available via GitHub at: <https://github.com/megskelton/gad-sympt-metagwas>.

References

- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* **403**, 2133–2161 (2024).
- Archer, C., Turner, K., Kessler, D., Mars, B. & Wiles, N. Trends in the recording of anxiety in UK primary care: a multi-method approach. *Soc. Psychiatry Psychiatr. Epidemiol.* **57**, 375–386 (2022).
- Goodwin, R. D., Weinberger, A. H., Kim, J. H., Wu, M. & Galea, S. Trends in anxiety among adults in the United States, 2008–2018: rapid increases among young adults. *J. Psychiatr. Res.* **130**, 441–446 (2020).
- GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry* **9**, 137–150 (2022).
- Rapaport, M. H., Clary, C., Fayyad, R. & Endicott, J. Quality-of-life impairment in depressive and anxiety disorders. *Am. J. Psychiatry* **162**, 1171–1178 (2005).
- Meier, S. M. & Deckert, J. Genetics of anxiety disorders. *Curr. Psychiatry Rep.* **21**, 16 (2019).
- Pratt, L. A., Druss, B. G., Manderscheid, R. W. & Walker, E. R. Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey. *Gen. Hosp. Psychiatry* **39**, 39–45 (2016).
- Wittchen, H. U., Zhao, S., Kessler, R. C. & Eaton, W. W. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. *Arch. Gen. Psychiatry* **51**, 355–364 (1994).
- Pavlova, B., Perlis, R. H., Alda, M. & Uher, R. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. *Lancet Psychiatry* **2**, 710–717 (2015).
- Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R. & Walters, E. E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch. Gen. Psychiatry* **62**, 617–627 (2005).
- Hollocks, M. J., Lerh, J. W., Magiati, I., Meiser-Stedman, R. & Brugha, T. S. Anxiety and depression in adults with autism spectrum disorder: a systematic review and meta-analysis. *Psychol. Med.* **49**, 559–572 (2019).
- Achim, A. M. et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. *Schizophr. Bull.* **37**, 811–821 (2011).
- Ask, H. et al. Genetic contributions to anxiety disorders: where we are and where we are heading. *Psychol. Med.* **51**, 2231–2246 (2021).
- Ozsivadjian, A., Knott, F. & Magiati, I. Parent and child perspectives on the nature of anxiety in children and young people with autism spectrum disorders: a focus group study. *Autism* **16**, 107–121 (2012).
- Chadwick, P., Kaur, H., Swelam, M., Ross, S. & Ellett, L. Experience of mindfulness in people with bipolar disorder: a qualitative study. *Psychother. Res.* **21**, 277–285 (2011).
- Cheesman, R. et al. Extracting stability increases the SNP heritability of emotional problems in young people. *Transl. Psychiatry* **8**, 223 (2018).
- Otowa, T. et al. Meta-analysis of genome-wide association studies of anxiety disorders. *Mol. Psychiatry* **21**, 1391–1399 (2016).
- Meier, S. M. et al. Genetic variants associated with anxiety and stress-related disorders: a genome-wide association study and mouse-model study. *JAMA Psychiatry* **76**, 924–932 (2019).
- Purves, K. L. et al. A major role for common genetic variation in anxiety disorders. *Mol. Psychiatry* **25**, 3292–3303 (2020).
- Li, W. et al. Genome-wide meta-analysis, functional genomics and integrative analyses implicate new risk genes and therapeutic targets for anxiety disorders. *Nat. Hum. Behav.* **8**, 361–379 (2024).
- Verma, A. et al. Diversity and scale: genetic architecture of 2068 traits in the VA Million Veteran Program. *Science* **385**, eadj1182 (2024).
- Frilgkou, E. et al. Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study. *Nat. Genet.* **56**, 2036–2045 (2024).
- Strom, N. I. et al. Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling. *Nat. Genet.* **58**, 275–288 (2026).
- Lee, W. E., Wadsworth, M. E. J. & Hotopf, M. The protective role of trait anxiety: a longitudinal cohort study. *Psychol. Med.* **36**, 345–351 (2006).
- Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *BMJ* **332**, 1080 (2006).
- Levey, D. F. et al. Reproducible genetic risk loci for anxiety: results from ~200,000 participants in the Million Veteran Program. *Am. J. Psychiatry* **177**, 223–232 (2020).
- Skelton, M. et al. Genetic overlap between functional impairment and depression and anxiety symptom severity: evidence from the GLAD Study. *Psych. Med.* **55**, e224 (2025).
- Tesfaye, M. et al. Identification of novel genomic loci for anxiety symptoms and extensive genetic overlap with psychiatric disorders. *Psychiatry Clin. Neurosci.* **78**, 783–791 (2024).
- Thorp, J. G. et al. Symptom-level modelling unravels the shared genetic architecture of anxiety and depression. *Nat. Hum. Behav.* **5**, 1432–1442 (2021).
- Visscher, P. M. et al. Statistical power to detect genetic (co) variance of complex traits using SNP data in unrelated samples. *PLoS Genet.* **10**, e1004269 (2014).

31. Evans, L. M. & Keller, M. C. Using partitioned heritability methods to explore genetic architecture. *Nat. Rev. Genet.* **19**, 185 (2018).
32. Bulik-Sullivan, B. et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
33. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
34. Zhu, Z. et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat. Commun.* **9**, 224 (2018).
35. Zheng, Z. et al. Leveraging functional genomic annotations and genome coverage to improve polygenic prediction of complex traits within and between ancestries. *Nat. Genet.* **56**, 767–777 (2024).
36. Weissbrod, O. et al. Functionally informed fine-mapping and polygenic localization of complex trait heritability. *Nat. Genet.* **52**, 1355–1363 (2020).
37. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B* **82**, 1273–1300 (2020).
38. Amendola, L. M. et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. *Genome Res.* **25**, 305–315 (2015).
39. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
40. Li, Y. et al. Cross-ancestry genome-wide association study and systems-level integrative analyses implicate new risk genes and therapeutic targets for depression. *Nat. Hum. Behav.* **9**, 806–823 (2025).
41. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
42. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
43. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318–1330 (2020).
44. Gaspar, H. A., Hübel, C. & Breen, G. Drug Targetor: a web interface to investigate the human druggome for over 500 phenotypes. *Bioinformatics* **35**, 2515–2517 (2019).
45. Ren, L. et al. Anxiety disorders: treatments, models, and circuitry mechanisms. *Eur. J. Pharmacol.* **983**, 176994 (2024).
46. Carey, C. E. et al. Principled distillation of UK Biobank phenotype data reveals underlying structure in human variation. *Nat. Hum. Behav.* **8**, 1599–1615 (2024).
47. Sullivan, P. F. et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. *Mol. Psychiatry* **14**, 359–375 (2009).
48. Christiansen, G. B. et al. The sorting receptor SorCS3 is a stronger regulator of glutamate receptor functions compared to GABAergic mechanisms in the hippocampus. *Hippocampus* **27**, 235–248 (2017).
49. Breiderhoff, T. et al. Sortilin-related receptor SORCS3 is a postsynaptic modulator of synaptic depression and fear extinction. *PLoS ONE* **8**, e75006 (2013).
50. Yang, Z. et al. Investigating shared genetic basis across Tourette syndrome and comorbid neurodevelopmental disorders along the impulsivity–compulsivity spectrum. *Biol. Psychiatry* **90**, 317–327 (2021).
51. Sun, F. et al. Hippocampal gray matter volume alterations in patients with first-episode and recurrent major depressive disorder and their associations with gene profiles. *BMC Psychiatry* **25**, 134 (2025).
52. Yang, J., Wray, N. R. & Visscher, P. M. Comparing apples and oranges: equating the power of case–control and quantitative trait association studies. *Genet. Epidemiol.* **34**, 254–257 (2010).
53. Direk, N. et al. An analysis of two genome-wide association meta-analyses identifies a new locus for broad depression phenotype. *Biol. Psychiatry* **82**, 322–329 (2017).
54. Cai, N. et al. Minimal phenotyping yields genome-wide association signals of low specificity for major depression. *Nat. Genet.* **52**, 437–447 (2020).
55. Huang, L. et al. Polygenic analyses show important differences between major depressive disorder symptoms measured using various instruments. *Biol. Psychiatry* **95**, 1110–1121 (2024).
56. Strom, N. I. et al. Genome-wide association study of obsessive–compulsive symptoms including 33,943 individuals from the general population. *Mol. Psychiatry* **29**, 2714–2723 (2024).
57. American Psychiatric Association (ed.) *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)* (American Psychiatric Association Publishing, 2022); <https://doi.org/10.1176/appi.books.9780890425787>
58. Morneau-Vaillancourt, G. et al. The genetic and environmental hierarchical structure of anxiety and depression in the UK Biobank. *Depress. Anxiety* **37**, 512–520 (2020).
59. ter Kuile, A. R. et al. Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder. Preprint at medRxiv <https://doi.org/10.64898/2026.02.06.26345742> (2026).
60. Zugman, A. et al. Mega-analysis methods in ENIGMA: the experience of the generalized anxiety disorder working group. *Hum. Brain Mapp.* **43**, 255–277 (2022).
61. Funk, J., Morneau-Vaillancourt, G., Palaiologou, E. & Eley, T. Heritability of generalised anxiety stability—a longitudinal twin study among young adults. *Psychol. Med.* **5**, e180 (2025).
62. Gillespie, N. A. et al. Do the genetic or environmental determinants of anxiety and depression change with age? A longitudinal study of Australian twins. *Twin Res.* **7**, 39–53 (2004).
63. Rosseel, Y. lavaan: an R package for structural equation modeling. *J. Stat. Softw.* **48**, 1–36 (2012).
64. Mitchell, B. L. et al. The Australian Genetics of Depression Study: new risk loci and dissecting heterogeneity between subtypes. *Biol. Psychiatry* **92**, 227–235 (2022).
65. Boyd, A. et al. Cohort profile: the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. *Int. J. Epidemiol.* **42**, 111–127 (2013).
66. Fraser, A. et al. Cohort profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int. J. Epidemiol.* **42**, 97–110 (2013).
67. Preisig, M. et al. The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. *BMC Psychiatry* **9**, 9 (2009).
68. Milani, L. et al. The Estonian Biobank’s journey from biobanking to personalized medicine. *Nat. Commun.* **16**, 3270 (2025).
69. Smith, B. H. et al. Cohort profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. *Int. J. Epidemiol.* **42**, 689–700 (2013).
70. Davies, M. R. et al. The Genetic Links to Anxiety and Depression (GLAD) Study: online recruitment into the largest recontactable study of depression and anxiety. *Behav. Res. Ther.* **123**, 103503 (2019).
71. Sijtsma, A. et al. Cohort profile update: lifelines, a three-generation cohort study and biobank. *Int. J. Epidemiol.* **51**, e295 (2022).

72. Deckert, J. et al. GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder. *Mol. Psychiatry* **22**, 1431–1439 (2017).
73. Magnus, P. et al. Cohort profile update: the Norwegian Mother and Child Cohort Study (MoBa). *Int. J. Epidemiol.* **45**, 382–388 (2016).
74. Heinig, I. et al. Optimizing exposure-based CBT for anxiety disorders via enhanced extinction: design and methods of a multicentre randomized clinical trial. *Int. J. Methods Psychiatr. Res.* **26**, e1560 (2017).
75. Lockhart, C. et al. Twins Early Development Study (TEDS): a genetically sensitive investigation of mental health outcomes in the mid-twenties. *JCPP Adv.* **3**, e12154 (2023).
76. Oldehinkel, A. J. et al. Cohort profile update: the TRacking Adolescents' Individual Lives Survey (TRAILS). *Int. J. Epidemiol.* **44**, 76–76n (2015).
77. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
78. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).
79. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
80. Adams, M. J. et al. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. *Cell* **188**, 640–652 (2025).
81. Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
82. Cerezo, M. et al. The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity. *Nucleic Acids Res.* **53**, D998–D1005 (2025).
83. Lin, S.-H., Brown, D. W. & Machiela, M. J. LDtrait: an online tool for identifying published phenotype associations in linkage disequilibrium. *Cancer Res.* **80**, 3443–3446 (2020).
84. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
85. Gupta, P. et al. A genome-wide investigation into the underlying genetic architecture of personality traits and overlap with psychopathology. *Nat. Hum. Behav.* **8**, 2235–2249 (2024).
86. Gilchrist, L. et al. Depression symptom-specific genetic associations in clinically diagnosed and proxy case Alzheimer's disease. *Nat. Ment. Health* **3**, 212–228 (2025).
87. Lupton, M. K. et al. A prospective cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA). *NeuroImage Clin.* **29**, 102527 (2021).
88. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. *Genet. Epidemiol.* **36**, 214–224 (2012).
89. Ramasamy, A. et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat. Neurosci.* **17**, 1418–1428 (2014).
90. Schmitt, A. D. et al. A compendium of chromatin contact maps reveals spatially active regions in the human genome. *Cell Rep.* **17**, 2042–2059 (2016).
91. Giusti-Rodriguez, P. M. D. & Sullivan, P. F. Using three-dimensional regulatory chromatin interactions from adult and fetal cortex to interpret genetic results for psychiatric disorders and cognitive traits. Preprint at *bioRxiv* <https://doi.org/10.1101/406330> (2018).
92. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Res.* **40**, D1100–D1107 (2012).
93. Zdrazil, B. et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. *Nucleic Acids Res.* **52**, D1180–D1192 (2024).
94. Freshour, S. L. et al. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsourcing efforts. *Nucleic Acids Res.* **49**, D1144–D1151 (2021).
95. Gaziano, J. M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. *J. Clin. Epidemiol.* **70**, 214–223 (2016).

Acknowledgements

AGDS: We are indebted to the participants for giving their time to contribute to this study. We thank all the people who helped in the conception, implementation, beta testing, media campaign and data cleaning. The AGDS was funded by grant 108663 (to N.G.M.) from the Australian National Health and Medical Research Council (NHMRC). This work was supported by NHMRC Investigator Grants 2017176 to B.L.M., 1173790 to N.R.W., 1172990 to N.G.M., 1172917 and 2025674 to S.E.M. and 2016346 to I.B.H. E.M.B. received funding from the PRE-EMPT NHMRC Centre for Research Excellence (1198304 to E.M.B.) and the University of Queensland Health Research Accelerator Program. ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council (MRC) and Wellcome (grant reference 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and A.S.F.K. will serve as guarantor for the ALSPAC contents of this article. Genome-wide genotyping data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. CoLaus/PSyCoLaus: The CoLaus/PSyCoLaus study was supported by unrestricted research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (grants 3200B0-105993, 3200B0-118308, 33CS0-122661, 33CS30-139468, 33CS30-148401 and 33CS30-177535 to M.P., and grants 3247730_204523 and 320030_220190) and the Swiss Personalized Health Network (grant 2018DRI01). Estonian Biobank: We acknowledge the Estonian Biobank participants and the Estonian Biobank Research Team (A. Metspalu, L. Milani, T. Esko, R. Mägi, M. Metspalu, M. Nelis and G. Hudjashov). Data analysis was carried out in part in the High-Performance Computing Center of the University of Tartu. This research was supported by the Estonian Research Council (grant PSG615 to K.L.) and the Estonian Centre of Excellence for Well-Being Sciences, funded by grant TK218 (to K.L.) from the Estonian Ministry of Education and Research. The research was conducted using the Estonian Center of Genomics/Roadmap II funded by the Estonian Research Council (project number TT17). Analyses were performed using data according to release application 6-7/GI/16880. Generation Scotland (GS): We thank the participants and staff of GS. The work presented is supported by Wellcome Trust (226770/Z/22/Z, 220857/Z/20/Z and 216767/Z/19/Z to A.M.M.) and UK Research and Innovation (MR/Z50354X/1 and MR/Z000548/1 to A.M.M.). Genotyping of GS samples was funded by the MRC and Wellcome Trust (104036/Z/14/Z). GS also received support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). GLAD+ (including NIHR BioResource): We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health and Care Research (NIHR), NHS Blood and Transplant and Health Data Research UK as part of the Digital Innovation

Hub Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We gratefully acknowledge the participation of the NIHR BioResource Centre Maudsley (grant reference NIHR203318 to G.B.), Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London volunteers, and we thank the staff for their help with volunteer recruitment. We thank the NIHR Biomedical Research Centre at South London and the Maudsley NHS Foundation Trust and King's College London for funding. This study represents independent research supported by the NIHR Biomedical Research Centre BioResource at South London and Maudsley NHS Foundation Trust and King's College London. We gratefully acknowledge capital equipment funding from the Maudsley Charity (grant reference 980 to G.B.) and Guy's and St Thomas's Charity (grant reference STR130505 to G.B.). Lifelines Cohort Study: The Lifelines Biobank initiative has been made possible by funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG the Netherlands), University of Groningen and the Northern Provinces of the Netherlands. The generation and management of GWAS genotype data for the Lifelines Cohort Study is supported by the UMCG Genetics Lifelines Initiative (UGLI). UGLI is partly supported by a Spinoza Grant from NWO, awarded to C. Wijmenga. We acknowledge the services of the Lifelines Cohort Study, the contributing research centres delivering data to Lifelines and all the study participants. MEGA TRR58: This project was funded by the German Research Foundation (DFG)—project number 44541416 TRR 58 'Fear, Anxiety, Anxiety Disorders', project Z02/1-3 to J.D. and K.D. and project number 499262975 to A.E.-L. and Andre Pittig. This work was supported by the DFG (grants FOR2107 DA1151/5-1, DA1151/5-2, DA1151/9-1, DA1151/10-1 and DA1151/11-1 to U.D.; SFB/TRR 393, project grant number 521379614) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan 3/022/22 to U.D.). We thank M. Kuhn for help with data acquisition. MoBa: We are grateful to all the participating families in Norway who take part in this on-going cohort study. For generating high-quality genomic data, we thank the Norwegian Institute of Public Health, the HARVEST collaboration, the NORMENT Centre at the University of Oslo, the Center for Diabetes Research at the University of Bergen, deCODE Genetics, the Research Council of Norway, the South-Eastern and Western Norway Regional Health Authorities, the ERC AdG, Stiftelsen KG Jebsen, the Trond Mohn Foundation and the Novo Nordisk Foundation. The MoBa analysis was performed on the Tjeneste for Sensitive Data (TSD) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT), using resources provided by Sigma2—the National Infrastructure for High Performance Computing and Data Storage in Norway (UNINETT). H.A. and J.H.P. were funded by the Research Council of Norway (RCN numbers 324620 and 336085) and NordForsk (156298 and 230738). A.H. and L.J.H. were funded by the South-Eastern Norway Regional Health Authority (2020022, 2022083 and 2026069) and the Research Council of Norway (336085). E.C.C. was supported by funding from the Research Council of Norway (274611) and the South-Eastern Norway Regional Health Authority (2021045). MVP: We thank MVP staff, researchers and volunteers who have contributed to MVP, and especially participants who previously served their country in the military and now generously agreed to enrol in the study (see <https://www.research.va.gov/mvp/> for more details). The citation details for MVP can be found in ref. 95. This research is based on data from the MVP, Office of Research and Development, Veterans Health Administration, and was supported by the Veterans Administration (VA) MVP award number 000. PISA: PISA was funded by the NHMRC of Australia (grant identifier APP1095227 to N.G.M. and M.K.L.). PROTECT-AD: One of nine research consortia in the German federal research programme 'Research Network on Mental Disorders', funded by the Federal Ministry of Education and Research (BMBF; <http://www.fzpe.de>), project P5 (grant number 01EE1402F to J.D. and K.D.). A

complete list of project publications can be found at www.fzpe.de. Recruitment of PROTECT-AD was funded by the BMBF (project P1, 01EE1402A to J.H.). The presented work was derived from projects P1 and P5. Principal investigators and individuals responsible for recruitment are: U. Wittchen, A. Pittig, I. Heinig, J. Hoyer (Dresden), A. Ströhle and J. Fydrich (Berlin), A. Hamm and J. Richter (Greifswald), V. Arolt, U. Dannlowski and K. Kölbeck (Münster), S. Schneider and J. Margraf (Bochum), T. Kircher, B. Straube and W. Rief (Marburg), J. Deckert, K. Domschke, U. Lueken and P. Pauli (Würzburg) and P. Neudeck (Cologne). We thank the following individuals for their help: J. Dehler, D. Westphal, K. Hummel, J. Hoyer (Dresden), V. Pflug, D. Adolph, C. Mohr, J. Cwik (Bochum), M. Hollandt, A. Pietzner, J. Neubert (Greifswald), C. Konrad, Y. Yang, I. Ridderbusch, A. Wroblewski, H. Christiansen, A. Maenz, S. Tennie, J. Thierschmidt (Marburg), M. Romanos, K. Zierhut, K. Dickhöver, M. Winkler, M. Stefanescu, C. Ziegler, H. Weber (Würzburg), N. Weber, S. Schauenberg, S. Wriedt, C. Heitmann (Münster), C. im Brahm, A. Evers (Cologne), I. Alt, S. Bischoff, J. Mumm, J. Plag, A. Schreiner and S. Meska (Berlin). X. Grählert and M. Käßpler of the Coordinating Centre for Clinical Trials (KKS) data centre (Dresden) provided support with the electronic data assessment and data banking. E. Stolzenburg, S. Bologov and K. Bley provided administrative support. TEDS: We gratefully acknowledge the ongoing contribution of the TEDS participants and their families. TEDS is funded by a UK MRC programme grant (MR/V012878/1) to T.C.E. (previously MR/M021475/1 to R. Plomin). TRAILS: This research is part of the TRacking Adolescents' Individual Lives Survey (TRAILS). Participating centres of TRAILS include various departments of the University Medical Center and University of Groningen, the University of Utrecht and the Parnassia Psychiatric Institute, all in the Netherlands. TRAILS has been financially supported by grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council programme grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grant 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001 (A.J.O.); Social Sciences Council project grants GB-MaGW 452-04-314 (A.J.O.) and GB-MaGW 452-06-004; ZonMw Longitudinal Cohort Research on Early Detection and Treatment in Mental Health Care grant 636340002; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013 and 481-11-001; NWO Vici 016.130.002 (A.J.O.), 453-16-007/2735 and Vi.C 191.021 and NWO Gravitation 024.001.003 (A.J.O.)), the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), the European Research Council (ERC-2017-STG-757364 and ERC-CoG-2015-681466), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32) (C.A.H.), the Gratema Foundation, the Jan Dekker foundation, the participating universities, and Accare Centre for Child and Adolescent Psychiatry. Statistical analyses were carried out on the Genetic Cluster Computer (<http://www.geneticcluster.org>), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation. We are grateful to everyone who participated in this research or worked on this project to make it possible. UK Biobank: This research has been conducted using the UK Biobank Resource under application number 82087. This work uses data provided by patients and collected by the NHS as part of their care and support. 23andme: This article uses summary statistics from pre-existing analyses with 23andme participants to perform genetic correlations with our phenotype. We thank the research participants and employees of 23andMe for making this work possible. Additional: We acknowledge the use of the King's College London research computing facility, CREATE (<https://doi.org/10.18742/rmvf-m076>). N.S. received funding from a UKRI Future Leaders Fellowship (grant number MR/T04327X/1) and the UK Dementia Research Institute award number

UK DRI-5008 through UK DRI Ltd. N.G.M. acknowledges funding from the NHMRC. O.A.A. received EU, RCN, NIH, NordForsk and SouthEast Health Authority funding. A.S.F.K. is supported by a Wellcome Early Career Award (grant reference 227063/Z/23/Z). E.C.C. is a member of the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the MRC and the University of Bristol (MC_UU_00032/1). L.J.H. was supported by funding from the Norwegian South-East Regional Health Authority (grant numbers 2021045, 2019097 and 2022083). A.H. acknowledges the South-Eastern Norway Regional Health Authority (number 2020022) and the Research Council of Norway (numbers 274611 and 336085). J.H. acknowledges NIMH 5R01MH124847. S.E.M. acknowledges funding from NHMRC APP1172917 and APP2025674. B.L.M. was supported by an NHMRC Investigator Grant (APP2017176). A.R.t.K. was supported by the ERC under the European Union's Horizon 2020 research and innovation programme (grant agreement number 863981). G.M.-V. is supported by a Banting Postdoctoral Fellowship from the Social Sciences and Humanities Research Council of Canada (grant reference 202309BPF-510174-293475). This phase of the Psychiatric Genomics Consortium is part-funded by the US National Institutes of Health (MH124873). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions

T.C.E., J.R.I.C. and G.B. supervised the study. A core team of T.C.E., J.R.I.C., G.B., M.S., B.L.M., E.A., D.L., A.R.t.K., R.W. and C.A.H. designed and directed the study. T.C.E., J.R.I.C., G.B., M.S., B.L.M., E.A., D.L., G.M.-V., A.R.t.K. and R.W. drafted the article and implemented revisions. M.S., B.L.M., E.A.-L., D.L., G.M.-V., A.E.M., A.R.t.K. and R.W. conducted data analysis and data visualization. M.S., B.L.M., D.L., R.W., M.J.A., E.M.B., E.C.C., P.Z.G., L.J.H., J.H., K.K., A.S.F.K., S.P., J.H.P., G.P., E.C., P.J.v.D.M., O.A.A., A.E.-L., A.H., N.S., B.V., H.W., C.A., H.A., U.D., J.D., K.D., I.B.H., K.L., T.B.L., U.L., M.K.L., S.E.M., A.M.M., A.J.O., M.P., A.R., H.S., J.T.R.W., C.A.H., N.G.M., G.B., J.R.I.C. and T.C.E. provided samples (concept and/or design for an individual study, acquired data for individual study and/or analysis and/or interpretation of results from individual study). All authors discussed the results, provided feedback on the draft of the article and approved the final version.

Competing interests

G.B. has received honoraria, research or conference grants and consulting fees from Illumina, Otsuka and COMPASS Pathfinder Ltd. O.A.A. served as a consultant for Precision-Health.ai and Cortechs.ai, and has received speaker's honorarium from BMS, Lundbeck, Otsuka, Sunovion, Janssen and Lilly. K.D. is a member of the Neurotorium Editorial Board of the Lundbeck Foundation and has received speaker's honoraria by Janssen Cilag GmbH, not related to the subject of this paper. I.B.H. is a professor of psychiatry and the codirector of Health and Policy, Brain and Mind Centre, University of Sydney.

He has led major public health and health service development in Australia, particularly focusing on early intervention for young people with depression, suicidal thoughts and behaviours and complex mood disorders. He is active in the development through codesign, implementation and continuous evaluation of new health information and personal monitoring technologies to drive highly personalized and measurement-based care. He holds a 3.2% equity share in Innowell Pty Ltd that is focused on digital transformation of mental health services. A.M.M. has received research support from Eli Lilly, Janssen and The Sackler Trust. A.M.M. has also received speaker fees from Illumina and Janssen. J.D. is a member of the board of the German Society of Biological Psychiatry and is on the scientific advisory boards of non-profit organizations and foundations. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41562-026-02476-7>.

Correspondence and requests for materials should be addressed to Thalia C. Eley.

Peer review information *Nature Human Behaviour* thanks Alexander Neumann, Hon-Cheong So and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

Megan Skelton ^{1,161}, Brittany L. Mitchell ^{2,3,4,161}, Elham Assary ¹, Danyang Li¹, Genevieve Morneau-Vaillancourt ⁵, Alan E. Murphy ^{6,7}, Abigail R. ter Kuile ⁸, Rujia Wang^{1,9}, Mark J. Adams ¹⁰, Enda M. Byrne ¹¹, Elizabeth C. Corfield ^{12,13,14,15}, Poppy Z. Grimes ¹⁰, Laurie J. Hannigan ^{12,13,14}, Jihua Hu^{2,3}, Kadri Kõiv ¹⁶, Alex S. F. Kwong ^{10,14}, Sergi Papiol^{17,18}, Johanne H. Pettersen ¹², Giorgio Pistis ¹⁹, Enrique Castelao¹⁹, Nora I. Strom ^{20,21,22,23}, Peter J. van der Most ²⁴, Anxiety Disorders Working Group of the Psychiatric Genomics Consortium*, GLAD+ authors, Lifelines Cohort Study*, NIHR BioResource*, PROTECT-AD Consortium*, Ole A. Andreassen^{25,26}, Angelika Erhardt-Lehmann^{17,27}, Alexandra Havdahl ^{12,13,14,28}, Nathan Skene^{6,7}, Brad Verhulst ²⁹, Heike Weber ²⁷, Chérie Armour³⁰, Helga Ask ¹², William E. Copeland ³¹, Udo Dannlowski ^{32,33,34,35}, Jürgen Deckert ^{27,36}, Katharina Domschke ^{37,38}, Ian B. Hickie ³⁹, Kelli Lehto¹⁶, Tina B. Lonsdorf ^{40,41}, Ulrike Lueken ^{20,27,38}, Michelle K. Lupton ^{2,3,4}, Sarah E. Medland ^{2,42,43}, Andrew M. McIntosh ¹⁰, Albertine J. Oldehinkel ⁴⁴, Martin Preisig ¹⁹, Andreas Reif ^{45,46}, Harold Snieder ²⁴, James T. R. Walters ⁴⁷, Naomi R. Wray ^{48,49}, Catharina A. Hartman ⁴⁴, Nicholas G. Martin^{2,3}, John M. Hettema ²⁹, Gerome Breen ^{1,9,162}, Jonathan R. I. Coleman ^{1,9,162} & Thalia C. Eley ^{1,9,162} ✉

¹Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. ²Brain and Mental Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ³School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. ⁴School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia. ⁵Research Centre of the Montreal University Institute of Mental Health, University of Montreal, Montreal, Quebec, Canada. ⁶UK Dementia Research Institute at Imperial College London, London, UK. ⁷Department of Brain Sciences, Imperial College London, London, UK. ⁸Department of Clinical, Educational, and Health Psychology, University College London, London, UK. ⁹National Institute for Health and Care Research Maudsley Biomedical Research Centre, South London and Maudsley NHS Trust, London, UK. ¹⁰Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ¹¹The University of Queensland, Child Health Research Centre, Brisbane, Queensland, Australia. ¹²PsychGen Centre for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo, Norway. ¹³Psychiatric Genetic Epidemiology Group, Research Department, Lovisenberg Diaconal Hospital, Oslo, Norway. ¹⁴Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. ¹⁵MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK. ¹⁶Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia. ¹⁷Department Clinical Translation, Max Planck Institute of Psychiatry, Munich, Germany. ¹⁸Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain. ¹⁹Department of Psychiatry, Lausanne University Hospital (CHUV) and University of Lausanne, Prilly, Switzerland. ²⁰Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany. ²¹Institute of Psychiatric Phenomics and Genomics, LMU Munich, University Hospital, Munich, Germany. ²²Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Solna, Sweden. ²³Department of Biomedicine, Aarhus University, Aarhus, Denmark. ²⁴Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ²⁵Centre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ²⁶Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. ²⁷Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany. ²⁸PROMENTA Research Centre, Department of Psychology, University of Oslo, Oslo, Norway. ²⁹Department of Psychiatry and Behavioral Sciences, Texas A&M University, Bryan, TX, USA. ³⁰Stress, Trauma and Related Conditions Research Centre (STARCO), School of Psychology, Queen's University Belfast, Belfast, UK. ³¹Department of Psychiatry, University of Vermont, Burlington, VT, USA. ³²Institute for Translational Psychiatry, University of Münster, Münster, Germany. ³³Department of Psychiatry, Medical School and University Medical Center OWL, Protestant Hospital of the Bethel Foundation, Bielefeld University, Bielefeld, Germany. ³⁴German Center for Mental Health (DZPG), Site Jena Magdeburg Halle, Jena, Germany. ³⁵Center for Intervention and Research on Adaptive and Maladaptive Brain Circuits Underlying Mental Health (C-I-R-C), Site Jena Magdeburg Halle, Jena, Germany. ³⁶Institute of Clinical Epidemiology and Biometrics, University of Würzburg, Würzburg, Germany. ³⁷Department of Psychiatry and Psychotherapy, Faculty of Medicine, Medical Center – University of Freiburg, University of Freiburg, Freiburg, Germany. ³⁸German Center for Mental Health (DZPG), Partner Site Berlin-Potsdam, Berlin, Germany. ³⁹Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia. ⁴⁰Experimental Medicine, Systems Neuroscience, University Medical Center Hamburg Eppendorf, Hamburg, Germany. ⁴¹Psychology, Biological Psychology and Cognitive Neuroscience, University of Bielefeld, Bielefeld, Germany. ⁴²School of Psychology, The University of Queensland, Brisbane, Queensland, Australia. ⁴³School of Psychology and Counselling, Queensland University of Technology, Brisbane, Queensland, Australia. ⁴⁴Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ⁴⁵Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Medical Centre Frankfurt, Frankfurt am Main, Germany. ⁴⁶Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany. ⁴⁷National Centre for Mental Health and Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK. ⁴⁸Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia. ⁴⁹Department of Psychiatry, University of Oxford, Oxford, UK. ¹⁶¹These authors contributed equally: Megan Skelton, Brittany L. Mitchell. ¹⁶²These authors jointly supervised this work: Jerome Breen, Jonathan R. I. Coleman, Thalia C. Eley. *Lists of authors and their affiliations appear at the end of the paper. ✉e-mail: thalia.eley@kcl.ac.uk

Anxiety Disorders Working Group of the Psychiatric Genomics Consortium

Nora I. Strom^{20,21,22,23}, Brad Verhulst²⁹, Silviu-Alin Bacanu⁵⁰, Rosa Cheesman²⁸, Kirstin L. Purves¹, Hüseyin Gedik^{51,52,53}, Brittany L. Mitchell^{2,3,4,161}, Alex S. F. Kwong^{10,14}, Annika B. Faucon⁵⁴, Kritika Singh^{55,56}, Sarah E. Medland^{2,42,43}, Lucia Colodro-Conde^{2,42}, Kristi Krebs¹⁶, Per Hoffmann^{57,58}, Stefan Herms^{57,58,59}, Jan Gehlen⁶⁰, Stephan Ripke^{61,62}, Swapnil Awasthi⁶¹, Teemu Palviainen⁶³, Elisa M. Tasanko⁶⁴, Roseann E. Peterson^{50,51}, Daniel E. Adkins⁶⁵, Andrew A. Shabalin⁶⁵, Mark J. Adams¹⁰, Matthew H. Iveson¹⁰, Archie Campbell⁶⁶, Laurent F. Thomas^{67,68,69,70}, Bendik S. Winsvold^{71,72,73}, Ole Kristian Drange^{25,26,74,75,76,77}, Sigrid Børte^{72,78,79}, Abigail R. ter Kuile⁸, Tan-Hoang Nguyen⁵³, Sandra M. Meier⁸⁰, Elizabeth C. Corfield^{12,13,14,15}, Laurie J. Hannigan^{12,13,14}, Daniel F. Levey^{81,82}, Darina Czamara⁸³, Heike Weber²⁷, Karmel W. Choi^{84,85}, Giorgio Pistis¹⁹, Baptiste Couvy-Duchesne^{2,48,86}, Sandra Van der Auwera⁸⁷, Alexander Teumer^{87,88}, Robert Karlsson⁸⁹, Miguel Garcia-Argibay^{89,90}, Donghyung Lee⁹¹, Rujia Wang^{1,9}, Ottar Bjerkeset^{74,92}, Eystein Stordal^{74,93}, Julia Bäckmann²², Giovanni A. Salum^{94,95}, Clement C. Zai^{96,97,98,99,100}, James L. Kennedy^{96,97,98}, Gwyneth Zai^{96,97,98}, Arun K. Tiwari^{96,97,98}, Stefanie Heilmann-Heimbach⁵⁷, Børge Schmidt¹⁰¹, Jaakko Kaprio⁶³, Martin M. Kennedy¹⁰², Joseph Boden¹⁰³, Alexandra Havdahl^{12,13,14,28}, Christel M. Middeldorp^{11,104}, Fabiana L. Lopes^{105,106}, Nirmala Akula¹⁰⁷, Francis J. McMahon^{107,108}, Elisabeth B. Binder⁸³, Lydia Fehm¹⁰⁹, Andreas Ströhle⁶¹, Enrique Castelao¹⁹, Henning Tiemeier^{110,111}, Dan J. Stein¹¹², David Whiteman¹¹³, Catherine Olsen¹¹³, Zachary Fuller¹¹⁴, Xin Wang¹¹⁴, Naomi R. Wray^{48,49}, Enda M. Byrne¹¹, Glyn Lewis¹¹⁵, Nicholas J. Timpson^{14,15}, Lea K. Davis⁵⁵, Ian B. Hickie³⁹, Nathan A. Gillespie⁵⁰, Lili Milani¹⁶, Johannes Schumacher⁶⁰, David P. Woldbye¹¹⁶, Andreas J. Forstner^{57,60,117}, Markus M. Nöthen⁵⁷, Iiris Hovatta¹¹⁸, John Horwood¹⁰³, William E. Copeland³¹, Hermine H. Maes^{50,53,119}, Andrew M. McIntosh¹⁰, Ole A. Andreassen^{25,26}, John-Anker Zwart^{72,78,79}, Ole Mors^{120,121}, Anders D. Børghlum^{23,121,122}, Preben B. Mortensen¹²³, Helga Ask¹², Ted Reichborn-Kjennerud^{12,76}, Jakob M. Najman¹²⁴, Murray B. Stein^{125,126}, Joel Gelernter^{81,127,128}, Yuri Milaneschi¹²⁹, Brenda W. Penninx¹²⁹, Dorret I. Boomsma^{130,131}, Eduard Maron^{132,133}, Angelika Erhardt-Lehmann^{17,27}, Christian Rück²², Tilo T. Kircher¹³⁴, Christiane A. Melzig^{135,136}

Georg W. Alpers¹³⁷, Volker Arolt¹³⁸, Katharina Domschke^{37,38}, Jordan W. Smoller^{84,85}, Martin Preisig¹⁹, Nicholas G. Martin^{2,3}, Michelle K. Lupton^{2,3,4}, Annemarie I. Luik¹³⁹, Andreas Reif^{45,46}, Hans J. Grabe⁸⁷, Henrik Larsson^{89,90}, Patrik K. Magnusson⁸⁹, Albertine J. Oldehinkel⁴⁴, Catharina A. Hartman⁴⁴, Gerome Breen^{1,9,162}, Anna R. Docherty^{50,140,141}, Hilary Coon¹⁴⁰, Rupert Conrad¹⁴², Kelli Lehto¹⁶, Jürgen Deckert^{27,36}, Thalia C. Eley^{1,9,162}, Manuel Mattheisen^{21,143,144} & John M. Hettema²⁹

⁵⁰Psychiatry, Virginia Commonwealth University, Richmond, VA, USA. ⁵¹Institute for Genomics in Health, Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA. ⁵²Life Sciences, Integrative Life Sciences Doctoral Program, Virginia Commonwealth University, Richmond, VA, USA. ⁵³Human and Molecular Genetics, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA. ⁵⁴Division of Medicine, Human Genetics, Vanderbilt University, Nashville, TN, USA. ⁵⁵Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ⁵⁶Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ⁵⁷Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany. ⁵⁸Department of Biomedicine, Human Genomics Research Group, University of Basel; University Hospital Basel, Basel, Switzerland. ⁵⁹Institute of Medical Genetics and Pathology, Medical Faculty, University Hospital Basel, Basel, Switzerland. ⁶⁰Center for Human Genetics, University of Marburg, Marburg, Germany. ⁶¹Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin, Berlin, Germany. ⁶²Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. ⁶³Helsinki Institute of Life Science, Institute for Molecular Medicine Finland – FIMM, University of Helsinki, Helsinki, Finland. ⁶⁴Faculty of Medicine, Department of Psychology and Logopedics, SleepWell Research Program, University of Helsinki, Helsinki, Finland. ⁶⁵School of Medicine, Department of Psychiatry, University of Utah, Salt Lake City, UT, USA. ⁶⁶College of Medicine and Veterinary Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. ⁶⁷Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. ⁶⁸HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. ⁶⁹BioCore – Bioinformatics Core Facility, Norwegian University of Science and Technology, Trondheim, Norway. ⁷⁰Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. ⁷¹Division of Clinical Neuroscience, Department of Research and Innovation, Oslo University Hospital, Oslo, Norway. ⁷²Department of Public Health and Nursing, HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway. ⁷³Department of Neurology, Oslo University Hospital, Oslo, Norway. ⁷⁴Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway. ⁷⁵Division of Mental Health, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. ⁷⁶NORMENT Centre, University of Oslo, Oslo, Norway. ⁷⁷Department of Psychiatry, Sørlandet Hospital, Kristiansand, Norway. ⁷⁸Division of Clinical Neuroscience, Department of Research and Innovation, Musculoskeletal Health, Oslo University Hospital, Oslo, Norway. ⁷⁹Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ⁸⁰Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada. ⁸¹Department of Psychiatry, Division of Human Genetics, Yale University School of Medicine, New Haven, CT, USA. ⁸²Psychiatry, Research, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA. ⁸³Department of Genes and Environment, Max Planck Institute of Psychiatry, Munich, Germany. ⁸⁴Psychiatry, Center for Precision Psychiatry, Massachusetts General Hospital, Boston, MA, USA. ⁸⁵Psychiatry, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ⁸⁶ARAMIS laboratory, Paris Brain Institute, Paris, France. ⁸⁷Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany. ⁸⁸Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. ⁸⁹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁹⁰School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. ⁹¹Department of Statistics, Miami University, Oxford, OH, USA. ⁹²Faculty of Nursing and Health Science, Nord University, Levanger, Norway. ⁹³Department of Psychiatry, Hospital Namsos, Nord-Trøndelag Health Trust, Namsos, Norway. ⁹⁴Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. ⁹⁵Child Psychiatry, National Institute of Developmental Psychiatry, São Paulo, Brazil. ⁹⁶Tanenbaum Centre for Pharmacogenetics, Molecular Brain Sciences Department, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. ⁹⁷Department of Psychiatry, Division of Neurosciences and Clinical Translation, University of Toronto, Toronto, Ontario, Canada. ⁹⁸Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. ⁹⁹Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. ¹⁰⁰Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA. ¹⁰¹Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany. ¹⁰²Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. ¹⁰³Psychological Medicine, University of Otago, Christchurch, New Zealand. ¹⁰⁴Child and Youth Mental Health Service, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia. ¹⁰⁵National Institute of Mental Health, Human Genetics Branch, National Institutes of Health, Bethesda, MD, USA. ¹⁰⁶Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA. ¹⁰⁷National Institute of Mental Health, Genetic Basis of Mood and Anxiety Disorders, National Institutes of Health, Bethesda, Maryland, USA. ¹⁰⁸Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA. ¹⁰⁹Department of Psychology, Zentrum für Psychotherapie, Humboldt-Universität zu Berlin, Berlin, Germany. ¹¹⁰Social and Behavioral Science, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. ¹¹¹Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, Netherlands. ¹¹²SAMRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa. ¹¹³Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ¹¹⁴23andMe, Sunnyvale, CA, USA. ¹¹⁵UCL Division of Psychiatry, University College London, London, UK. ¹¹⁶Department of Neuroscience, Laboratory of Neural Plasticity, University of Copenhagen, Copenhagen, Denmark. ¹¹⁷Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany. ¹¹⁸Faculty of Medicine, Department of Psychology and Logopedics and SleepWell Research Program, University of Helsinki, Helsinki, Finland. ¹¹⁹Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. ¹²⁰Department of Psychiatry, Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark. ¹²¹The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University, Aarhus, Denmark. ¹²²Center for Genomics and Personalised Medicine, Aarhus University, Aarhus, Denmark. ¹²³The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark. ¹²⁴Faculty of Medicine, School of Public Health, University of Queensland, Herston, Queensland, Australia. ¹²⁵Psychiatry, University of California San Diego, La Jolla, CA, USA. ¹²⁶School of Public Health, University of California San Diego, La Jolla, CA, USA. ¹²⁷Psychiatry Research, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA. ¹²⁸Departments of Genetics and Neuroscience, Yale University of Medicine, New Haven, CT, USA. ¹²⁹Amsterdam Neuroscience, Amsterdam Public Health, Amsterdam University Medical Center, Amsterdam, Netherlands. ¹³⁰Twin Register and Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. ¹³¹Amsterdam Public Health, Amsterdam University Medical Center, Amsterdam, the Netherlands. ¹³²Psychiatry, University of Tartu, Tartu, Estonia. ¹³³Department of Medicine, Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK. ¹³⁴Department of Psychiatry and Psychotherapy,

University of Marburg–UKGM, Marburg, Germany. ¹³⁵Department of Psychology, Clinical Psychology, University of Marburg, Marburg, Germany. ¹³⁶Department of Psychology, Biological and Clinical Psychology, University of Greifswald, Greifswald, Germany. ¹³⁷School of Social Sciences, Department of Psychology, University of Mannheim, Mannheim, Germany. ¹³⁸Department of Mental Health, Institute for Translational Psychiatry, University of Münster, Münster, Germany. ¹³⁹Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands. ¹⁴⁰School of Medicine, Psychiatry, University of Utah, Salt Lake City, UT, USA. ¹⁴¹School of Medicine, Psychiatry, Huntsman Mental Health Institute, University of Utah, Salt Lake City, UT, USA. ¹⁴²Department of Psychosomatic Medicine and Psychotherapy, University Hospital Münster, Münster, Germany. ¹⁴³Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada. ¹⁴⁴Computer Science, Dalhousie University, Halifax, Nova Scotia, Canada.

GLAD+ authors

Gerome Breen^{1,9,162}, Thalia C. Eley^{1,9,162}, Matthew Hotopf^{9,145}, Chérie Armour³⁰, Ian R. Jones¹⁴⁶, Andrew M. McIntosh¹⁰, James T. R. Walters⁴⁷, Daniel J. Smith¹⁰, Jonathan R. I. Coleman^{1,9,162}, Allan H. Young¹⁴⁵, Antony J. Cleare¹⁴⁵, Katrina A. S. Davis¹⁴⁵, Georgina Krebs¹, Katharine A. Rimes¹⁴⁵, David Veale¹⁴⁵, Roland Zahn¹⁴⁵, Molly R. Davies¹, Gursharan Kalsi¹, Shannon Bristow¹, Susannah C. B. Curzons¹, Henry C. Rogers¹, Katherine N. Thompson¹, Brett N. Adey¹, Ian Marsh¹, Dina Monssen¹, Monika McAtarsney-Kovacs¹, Charles J. Curtis¹, Jahnvi Arora¹, Saakshi Kakar¹, Laura Meldrum¹, Iona Smith¹, Le Roy Dowey^{147,148}, Victor Gault¹⁴⁷, Donald M. Lyall¹⁴⁹, Ruth K. Price¹⁴⁷, Keith G. Thomas¹⁴⁷, Zain Ahmad¹, Helena L. Davies¹, Christopher Hübel¹, Sang Hyuck Lee¹, Abigail R. ter Kuile⁸, Danyang Li¹, Yuhao “Leo” Lin¹, Jared G. Maina¹, Jessica Mundy¹, Alish Palmos¹, Alicia J. Peel¹, Kirstin L. Purves¹, Christopher Rayner¹, Megan Skelton^{1,161}, Rujia Wang^{1,9} & Johan Zvrskovec¹

¹⁴⁵Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. ¹⁴⁶Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. ¹⁴⁷School of Biomedical Sciences, Ulster University, Coleraine Campus, Northern Ireland, UK. ¹⁴⁸GreenLight Pharmaceuticals Limited, Dublin, Ireland. ¹⁴⁹School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Lifelines Cohort Study

Raul Aguirre-Gamboa¹⁵⁰, Patrick Deelen¹⁵⁰, Lude Franke¹⁵⁰, Jan A. Kuivenhoven¹⁵⁰, Esteban A. Lopera Maya¹⁵⁰, Ilja M. Nolte¹⁵⁰, Serena Sanna¹⁵⁰, Harold Snieder²⁴, Morris A. Swertz¹⁵⁰, Peter M. Visscher^{48,150,151}, Judith M. Vonk¹⁵⁰, Cisca Wijmenga¹⁵⁰ & Naomi R. Wray^{48,49}

¹⁵⁰University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ¹⁵¹Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

NIHR BioResource

John Bradley¹⁵², Nathalie Kingston¹⁵², Hannah Stark¹⁵², Carola Kanz¹⁵², Alexei Moulton¹⁵², Nigel Ovington¹⁵², Jacinta Lee¹⁵², Debbie Clapham-Riley¹⁵² & Katie Mills¹⁵²

¹⁵²NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.

PROTECT-AD Consortium

Uli Wittchen¹⁵³, Andre Pittig¹⁵⁴, Ingmar Heinig¹⁵⁵, Jürgen Hoyer¹⁵⁵, Andreas Ströhle⁶¹, Thomas Fydrich²⁰, Alfons Hamm¹³⁶, Jan Richter¹⁵⁶, Volker Arolt³², Udo Dannlowski^{32,33,34,35}, Katja Kölkebeck¹⁵⁷, Sylvia Schneider¹⁵⁸, Jürgen Margraf¹⁵⁸, Tilo T. Kircher¹³⁴, Benjamin Straube¹³⁴, Winfried Rief¹³⁵, Jürgen Deckert^{27,36}, Katharina Domschke^{37,38}, Ulrike Lueken^{20,27,38}, Paul Pauli¹⁵⁹ & Peter Neudeck¹⁶⁰

¹⁵³Psychiatric University Hospital, Ludwig-Maximilians-University München, Munich, Germany. ¹⁵⁴Translational Psychotherapy, Institute of Psychology, University of Göttingen, Göttingen, Germany. ¹⁵⁵Institute for Clinical Psychology and Psychotherapy, Technical University of Dresden, Dresden, Germany. ¹⁵⁶Department of Experimental Psychopathology, University of Hildesheim, Hildesheim, Germany. ¹⁵⁷Protestant Hospital of the Bethel Foundation, Department of Psychiatry and Psychotherapy, Bielefeld University, Medical School and University Medical Center OWL, Bielefeld, Germany. ¹⁵⁸Mental Health Research and Treatment Center, Department of Clinical Psychology and Psychotherapy, Ruhr-University Bochum, Bochum, Germany. ¹⁵⁹Department of Psychology I (Biological Psychology, Clinical Psychology and Psychotherapy), Institute of Psychology, University of Würzburg, Würzburg, Germany. ¹⁶⁰Protect-AD Study Site Cologne, Cologne, Germany.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-------------------------------------|--|
| n/a | Confirmed |
| ☐ | ☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☐ | ☒ A description of all covariates tested |
| ☐ | ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☐ | ☒ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	No software was used for data collection for the purpose of this specific study; pre-existing data was used. The contributing cohort studies used questionnaire software such as Qualtrics, OpenClinica, and REDCAP, as detailed in their original publications.
Data analysis	This information is provided in the Methods and Supplementary Tables. Individual GWAS were performed with REGENIE (v3.1 or 3.2; https://rgcgithub.github.io/regenie/), SAIGE (v 1.3; https://saigegit.github.io/SAIGE-doc/), or PLINK (2.0; https://www.cog-genomics.org/plink/). The meta-analysis was performed in METAL (v2020-05-05; https://csg.sph.umich.edu/abecasis/metal/download/). Estimates of genetic correlations, genomic inflation factor and LD score intercept were made using LDSC (v1.0.1; https://github.com/bulik/ldsc). Clumping, SNP-level gene annotation were performed in FUMA (v1.6.5; https://fuma.ctglab.nl/). Gene-based associations, gene-set and gene-tissue expression enrichment analyses were performed in MAGMA (v1.08; https://cncr.nl/research/magma/) via FUMA. LDTrait (https://ldlink.nih.gov/?tab=ldtrait) was used to cross-reference significant loci with those from the GWAS Catalog. BEDtools (v2.31.0) was used to inspect the overlap of loci with relevant studies unavailable in the GWAS Catalog. SBayesRC (v0.2; https://github.com/zhilizheng/SBayesRC) provided an estimate of SNP-based heritability and the calculation of polygenic scores. Conditional analyses were performed with the mtCOJO tool from GCTA software (v1.94.1). Fine-mapping was performed using PolyFun (v1.0.0; https://github.com/omerwe/polyfun) and SuSiE (v0.11.92; https://stephenslab.github.io/susier/). DrugTargetor (v1.3; https://drugtargetor.com/) was used to identify associations with individual drugs and drug classes. Data were prepared, described and visualised using R (v4; https://www.r-project.org/), the psych (https://cran.r-project.org/web/packages/psych/index.html), lavaan (https://cran.r-project.org/web/packages/lavaan/index.html) and tidyverse (https://cran.r-project.org/web/packages/tidyverse/index.html) packages. Analytical code for this study is available on Github: https://github.com/megskelton/gad-sympt-metagwas .

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

As per the data availability statement: Summary statistics will be made available on the PGC data-download page (<https://pgc.unc.edu/for-researchers/download-result>). Bona fide researchers can apply to access raw genomic data from the individual cohorts by contacting the relevant team or through the study website.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Genetically inferred sex, based on the X chromosome, was used as part of the quality control procedure in each cohort, as is typical in GWAS. Specifically, concordance between self-reported sex and genetically inferred sex was examined, and individuals with mismatches were removed, as these can indicate genotyping errors or sample contamination. For X chromosome analyses, cohorts either stratified by genetically inferred sex or included it as a covariate. The proportion of females in each contributing sample is provided in Table S1, with the overall proportion 48%. Sex and/or gender based analyses were not performed.

Reporting on race, ethnicity, or other socially relevant groupings

We used genetically inferred ancestry estimates based on the 1000 Genomes reference panel. All participants in the main analyses were of European inferred ancestry. Polygenic risk score analysis was performed in participant samples of South Asian and African inferred ancestry to test cross-ancestry transferability of our findings. No race, ethnicity, or other socially relevant groupings were shared for this project.

Population characteristics

A total of 14 cohorts contributed to this meta-analysis and characteristics varied across each of these. Information on individual study-specific inclusion criteria is available in Table S1 e.g. lifetime experience of anxiety or depression, country population-based. Sample descriptives (mean (SD) age and percentage female) are also provided in Table S1. The total sample was 693,869 individuals, 48% female, mean age 44 years (SD = 14). Information on genotyping methods for each cohort can be found in Table S3.

Recruitment

This information is detailed for each of the 14 cohorts in Table S1. In brief, recruitment methods included online recruitment, recruitment into national biobank studies, or within clinical settings via health service providers.

Ethics oversight

Details on the ethical approval for each contributing cohort study are provided in Table S1 (e.g. "Ethical approval for the GLAD Study and NBR COPING study was obtained from the London-Fulham Research Ethics Committee (REC reference 18/LO/1218 and 20/SW/0078, respectively, COPING project no. 282754.)."). This is referred to at the start of the Methods section of the manuscript.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☐ Life sciences ☒ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Quantitative

Research sample

Participants from established cohort studies who had previously provided generalised anxiety disorder symptom scores. This includes population-based cohort studies, studies recruiting based on a lifetime history of anxiety or depression, a population-based military veterans study, and a pregnancy-based population-based cohort study.

Sampling strategy

We identified samples with data on generalised anxiety symptom severity from communications within PGC-ANX and used as many as possible to maximise our sample size, excluding where a symptom measure had been used only in a small sample of participants as this would make subgroup measure-based secondary analyses underpowered for any meaningful conclusion. Convenience sampling was used in many cohorts, which relies on participants volunteering in response to recruitment materials, although some cohorts used population-based sampling whereby they invited all individuals within a defined population e.g. MoBa, TEDS. A power

	calculation using the GCTA calculator can be found in Table S6.
Data collection	Across cohorts, symptom measures were self-report questionnaires and are detailed in Table S1. Most were provided online. Genetic data was provided via blood or saliva samples.
Timing	This varies across cohorts but broadly the start and end dates for data collection are 2007 and 2023, respectively.
Data exclusions	This varies per cohort and is detailed in the supplementary tables and original cohort publications. Quality control exclusions included missingness of genetic or phenotypic data above a specified threshold, or evidence of contamination of genetic data.
Non-participation	This is a meta-analysis of pre-existing study data and therefore no dropout occurred in respect to this specific analysis.
Randomization	All participants were analysed as a single group.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Plants

Seed stocks	N/A
Novel plant genotypes	N/A
Authentication	N/A